



VACCINE INSIGHTS

Your content marketing partner for life sciences

MEDIA KIT 2024





Your content
marketing
partner for life
sciences

INDEX

| | |
|----------------------------|----|
| ▶ About | 3 |
| ▶ What can we do for you? | 5 |
| ▶ User demographics | 7 |
| ▶ Editorial calendar | 11 |
| ▶ Opportunities | 12 |
| ▶ Webinars | 13 |
| ▶ Expert roundtables | 16 |
| ▶ Articles | 17 |
| ▶ Interviews & podcasts | 18 |
| ▶ Video presentations | 20 |
| ▶ Infographics | 22 |
| ▶ Scientific illustrations | 23 |
| ▶ eBlasts | 24 |
| ▶ Premium services | 25 |
| ▶ Our other publications | 26 |

ABOUT

Vaccine Insights

Vaccine Insights is a peer-reviewed, open-access journal providing detailed coverage of the development and manufacture of novel vaccines. The journal brings together leading experts from pharma, biotech, academia, NGOs and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine R&D and delivery across all disease areas.

All content is available free of charge, and the written material is complemented by engaging formats such as webinars, infographics, animations, video and podcasts.

An online,
peer-reviewed,
open access
journal with a
translational focus




Is it important for **your company to demonstrate its capabilities** to scientists and/or business leaders making key technology platform decisions at an early stage in a vaccines development?

Do you need to **generate qualified leads** from companies involved in viral vector: mRNA vaccine development?

Are you looking to **provide educational materials** to individuals focused on preclinical, process or clinical development?

***Vaccine Insights* provides a unique online content marketing and lead-generation opportunity:**

- ▶ **Active engagement of key stakeholders** from across the global community all year round
- ▶ The chance to **target organizations at varying stages of the R&D pipeline**: Universities, spin-outs, biotechs, pharma, governments and NGOs, investors and analysts
- ▶ **An alternative to the ever-more expensive conference market**
- ▶ A means by which you can **access the people making the key new discoveries**, those individuals driving the delivery of safe and effective vaccines to patients, and those manufacturing the novel vaccines of the future



Vaccine Insights
provides a unique
online content marketing
and lead-generation
opportunity

WHAT CAN WE DO FOR YOU?

We can:

- ▶ Provide support in the **development of your content marketing strategy** and tactics for this sector, partnering with you in the development of your annual marketing plans
- ▶ Work closely with you to **create quality written, video and audio content** of high value to your target audience
- ▶ Offer you opportunities to **re-purpose scientific and educational content** you have already developed and make it available to a global audience
- ▶ **Raise your company's profile**, demonstrate your capabilities, and enhance your reputation as a thought-leader in the sector
- ▶ Play a key role in your **lead-generation activities**
- ▶ Ensure your leading scientists are seen as **Subject Matter Experts** throughout your target market
- ▶ **Create written content from video or audio**, ideal for increasing the reach, longevity and searchability of your data and other technical information

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

We can partner with you to develop high quality content to demonstrate your thought-leadership:

- ▶ Your own special focus issue or ebook on the topic of your choice
- ▶ Client case studies, interviews and co-presentations
- ▶ Peer reviewed articles, as well as editorials and commentaries
- ▶ Video presentations and roundtables
- ▶ Podcasts
- ▶ Infographics and animations
- ▶ Webinars, both live and on demand



USER DEMOGRAPHICS

Data by sector


- ▶ Biotech companies, including those at a relatively early stage of development.
- ▶ Prolific academic institutions, in particular those researching and testing new vaccines and vaccine-related technologies.
- ▶ Pharmaceutical companies and large biotechs with a major or growing focus on vaccines
- ▶ Government-funded organizations (such as BARDA) and NGOs such as Bill & Melinda Gates, PATH and IAVI
- ▶ Investors and analysts
- ▶ Solution and service providers



28%
Biotech



22%
Academic



18%
Large Vaccine
Manufacturer



8%
Government,
NGO, Public
Health Body



2%
Investor/
Analyst




22%
Solution/
Service Provider

We
currently
have 7,000
registered
users


Data by interest area & seniority

Vaccine Insights has a translational focus, featuring content of value to individuals along the R&D pipeline

- ▶ Discovery and basic research
- ▶ Preclinical development and translational R&D
- ▶ Clinical research
- ▶ Product development, process development, operations, logistics and manufacture
- ▶ Regulatory affairs, QA/QC and validation
- ▶ Business development, corporate management and licensing
- ▶ Formulation and delivery device development
- ▶ Public health and market access



Data by interest area & seniority (continued)



Data by location



EDITORIAL CALENDAR 2024

FEBRUARY

Respiratory diseases

- ▶ What's next for COVID vaccines?
- ▶ Respiratory syncytial virus (RSV):
- ▶ Invasive pneumococcal disease:
- ▶ Quantifying the risk from avian influenza and developing vaccines

APRIL

Manufacturing: upstream & raw materials

- ▶ How can manufacturers mitigate supply chain disruption?
- ▶ Localized vs centralized manufacturing
- ▶ Optimizing manufacturing footprint
- ▶ Scaling up vaccine manufacturing
- ▶ Novel expression systems for vaccine production
- ▶ Toward 100% chemically defined media, and easier generation of chemically defined media for individual processes
- ▶ Stainless steel vs single-use bioreactors for vaccine manufacture
- ▶ Maintaining "warm base" capacity for pandemic preparedness
- ▶ Challenges for training and tech transfer in vaccine manufacturing

MAY

RNA vaccines: research directions

- ▶ What will be the next testing ground for RNA vaccines? Where, when, and how will it prove its capabilities, and how much optimization will be needed on a case-by-case basis?
- ▶ Will RNA be broadly applicable or only suited to narrow applications such as pandemic vaccines?
- ▶ Evolving knowledge on mechanisms of action—decreasing reactogenicity while retaining potency
- ▶ Modifying mRNA vaccines to induce mucosal immune responses
- ▶ Adapting mRNA for use in personalized cancer vaccines
- ▶ How will the drive towards cancer vaccines impact infectious disease applications?
- ▶ Latest on next-gen RNA vaccine platforms
- ▶ Regulatory expectations for RNA vaccines—a platform technology?

JUNE

Understanding & enhancing immune responses

- ▶ Addressing immune imprinting/original antigenic sin for COVID-19 and other circulating RNA viruses
- ▶ Advances in immune profiling and understanding mechanisms of action
- ▶ Systems serology to decode vaccine-induced immune responses
- ▶ Understanding individual immune response to vaccination
- ▶ Standardizing data recording, storage, and sharing
- ▶ Embracing AI and machine learning for resolving immunological data and antigen design
- ▶ Understanding and targeting mucosal immunity
- ▶ Novel adjuvants, adjuvant platforms, and combinations

JULY

CMC & analytics

- ▶ Greater connection of CMC with clinical design and understanding quality expectations to avoid bottlenecks
- ▶ How will control strategy evolve with digital twin and digitalization?
- ▶ Patient-centric specifications
- ▶ What is needed from a CMC perspective to achieve CEPI's 100 days goal for pandemic vaccines? Risk-based approaches and innovations
- ▶ Advances in process analytical technology
- ▶ High-throughput tools for process development and analytics—forward-looking methods while remaining QC-compliant

SEPTEMBER

Preclinical & clinical research

- ▶ Closing the gap between preclinical and clinical results: better animal and in vitro models
- ▶ Measuring a wider range of immune markers
- ▶ Could evidence from human infection models support approvals?
- ▶ Clinical trials in populations with varied levels of immune competence
- ▶ Correlates of protection—regulators and licensure criteria
- ▶ Vaccine development for special populations
- ▶ Use of AI to clean up clinical data sets and reduce protocol deviations
- ▶ Making the most of real-world vaccine efficacy data
- ▶ Safety—understanding adverse events after vaccination
- ▶ What is a platform technology and how will they be regulated?
- ▶ Regulatory harmonization between regions

OCTOBER

RNA vaccines: formulation & production

- ▶ Sourcing and supply of raw materials—addressing the cost of goods
- ▶ Addressing expense, manufacturing complexity, and IP hurdles of LNPs with next-gen delivery particles
- ▶ Toward temperature-stable formulations
- ▶ Overcoming hurdles in production
- ▶ Analytical methods and control strategy for mRNA-LNP

NOVEMBER

Manufacturing: downstream, fill/finish, & delivery

- ▶ Exploring the need for better purification solutions across platforms
- ▶ The environmental sustainability of vaccine manufacturing operations
- ▶ Shared challenges and solutions for vaccines, biologics, and advanced therapy manufacturers
- ▶ Addressing extremes of volume
- ▶ Challenges and solutions in cold chain/controlled temperature chain

Vaccine Insights provide you with fantastic opportunities to:

- ▶ **Educate your target market** about your company's expertise, capabilities, and experience
- ▶ **Share your latest data** with organizations looking for partners and service providers in your field
- ▶ **Profile your executives and scientists** as thought-leaders and KOLs
- ▶ **Generate qualified leads** from across the global sector
- ▶ **Increase awareness** of your company's role in vaccines R&D

OPPORTUNITIES

We offer a broad range of options to help you reach your target audience, any of which can be tailored to match your current marketing and business development priorities. These include interviews, expert roundtables, podcasts, webinars, articles, video presentations, infographics, eblasts and more.

Any of our options can be tailored to match your current marketing and business development priorities.



WEBINARS

Presenting a webinar with Cell & Gene Therapy Insights gives you an efficient and cost-effective way to:

- ▶ Generate qualified leads from amongst the global cell and gene therapy community
- ▶ Demonstrate your company's expertise and capabilities
- ▶ Stimulate discussion around a topic of significant importance to your customers
- ▶ Educate individuals on crucial regulatory, scientific or technical issues
- ▶ Make a noise around a new product or service offering launch

Webinars can stand alone or can be included in a Spotlight, depending on the topic and timing fit.

Our
2024
webinar
schedule is
filling up fast.

Contact n.mccall@insights.bio to
discuss options & availability.



Presenting a webinar with us is an efficient and cost-effective way to generate qualified leads.

Our webinar packages include:


- ▶ As much support as you need in terms of topic selection and agenda development, format selection, and speaker panel identification and invitation
- ▶ Full hosting and technical support, including planning calls with panellists and rehearsals as needed
- ▶ A comprehensive promotional plan, including multiple email shots to our database, website and newsletter marketing, and social media
- ▶ A moderator from our editorial team to ensure the webinar runs smoothly on the day
- ▶ Registration and attendee lists for the webinar
- ▶ A report on the questions submitted during the live webinar so you can follow up directly with individuals afterwards and continue the discussion
- ▶ Hosting of the webinar recording on an indefinite basis with ongoing lead generation
- ▶ Webinar recording provided to you for hosting on your own site
- ▶ The option for us to publish an article based on the transcript of the webinar, repurposing your presentation into written format and making it search engine friendly

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

Examples of previous webinars for our clients:



Panel-style webinar with accompanying transcript-based article for Thermo Fisher Scientific



Presentation-style webinar with Q&A for Lonza



Live30 webinar: a 30 minute webinar focused on new technologies and their applications for OXGENE


You can view all of our on-demand webinars here.

EXPERT ROUNDTABLES

On-demand video expert roundtables provide powerful tools for you to generate qualified leads and/or position your thought-leader(s) at the heart of the debate around a topic of key importance to your company.

Our editorial team works closely with you to identify over-arching topics and discussion points, and to convene a panel of KOLs. We then liaise with the panel to define the final list of questions for discussion, video and edit the roundtable itself, and then produce a full article based on the transcript.

Video roundtable examples:



Video




Article

Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge



Video and article



Poster summarising key learning points

Strategies for scaling up and out in gene therapy manufacturing: addressing AAV's growing pains (for Corning)

ARTICLES

Free access publication of submitted articles remains the gold standard for sharing data with scientists across the sector.

Our sponsored article publication package includes full peer review, a license for you to reproduce the article on your own website, and a comprehensive two-month promotional package to maximise readership.

Examples of articles for our clients:

VECTOR BIOPROCESSING

Clarification of recombinant adeno-associated virus (rAAV) adherent culture

Cell & Gene Therapy Insights 2022; 8(2), 483–493
DOI: 10.1089/cgti.2022.070
PUBLISHED: 30 APRIL 2022

RESEARCH ARTICLE

Rajeshwar Chinnawar, Nicholas Marchand

In recent years the cell and gene therapy industries have been rapidly expanding, with two adeno-associated virus (AAV) and lentivirus. With clinical success comes the need to develop processes. As both of these vectors are produced in cells, the first step in their purification is to clarify the culture. This is a logical fit for batch processes. A combination of depth and membrane filtration is a logical fit for batch processes.

CELL & GENE THERAPY INSIGHTS

FIGURE 2 — Clarification of recombinant adeno-associated virus (rAAV) adherent culture. The figure shows three bar charts and one line graph. The bar charts show the percentage of rAAV in the supernatant and the percentage of rAAV in the culture medium. The line graph shows the percentage of rAAV in the supernatant over time.

488 DOI: 10.1089/cgti.2022.070

Clarification of recombinant adeno-associated virus (rAAV) & lentivirus from adherent culture for Pall Biotech

ANALYTICS: Enhancing accuracy & throughput

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform

Cell & Gene Therapy Insights 2022; 8(2), 231–240
DOI: 10.1089/cgti.2022.039
PUBLISHED: 16 MARCH 2022

INNOVATOR INSIGHT

Susan Darling

Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses (non-pathogenic, low immunogenicity, and can readily enter a variety of cell types), are highly complex molecules that present significant manufacturing challenges. There are a large number of serotypes to choose from, and the need to implement transfection processes that afford high yields of capsids containing the gene of interest and purification hurdles to overcome. From an analytical perspective, samples are getting more complex, more numerous, and require more complex analytical methods that involve complex method set ups, but results are needed in less time. Despite these challenges, developers of gene therapies must be able to understand the molecular liabilities of AAV vectors as soon as possible in the

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform

Cell & Gene Therapy Insights 2022; 8(2), 231–240
DOI: 10.1089/cgti.2022.039
PUBLISHED: 16 MARCH 2022

ABSTRACT — Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses (non-pathogenic, low immunogenicity, and can readily enter a variety of cell types), are highly complex molecules that present significant manufacturing challenges. There are a large number of serotypes to choose from, and the need to implement transfection processes that afford high yields of capsids containing the gene of interest and purification hurdles to overcome. From an analytical perspective, samples are getting more complex, more numerous, and require more complex analytical methods that involve complex method set ups, but results are needed in less time. Despite these challenges, developers of gene therapies must be able to understand the molecular liabilities of AAV vectors as soon as possible in the

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform for SCIEX

CELL THERAPY CMC AND QUALITY CONTROL

Characterization of a novel high-throughput, high-speed based image cytometric cell counting method

Cell & Gene Therapy Insights 2021; 7(4), 427–447
DOI: 10.1089/cgti.2021.070
PUBLISHED: 14 MAY 2021

RESEARCH ARTICLE

Jordan Bell, Yongyang Huang, Henry Qazi, Dmitry Kuksin, Jean Qiu, Bo Lin, Leo Li

Bioprocessing applications for cells and biologics have dramatically increased the number of immunotherapy. The cell counting time is a major bottleneck for traditional counting methods. Here we characterize and demonstrate a high-throughput, high-speed, and high-precision system. Here we characterize and demonstrate a high-throughput, high-speed, and high-precision system. Here we characterize and demonstrate a high-throughput, high-speed, and high-precision system.

CELL & GENE THERAPY INSIGHTS

FIGURE 4 — Characterization of a novel high-throughput, high-speed based image cytometric cell counting method. The figure shows three bar charts and one line graph. The bar charts show the percentage of cells in the supernatant and the percentage of cells in the culture medium. The line graph shows the percentage of cells in the supernatant over time.

440 DOI: 10.1089/cgti.2021.070

Characterization of a novel high-throughput, high-speed and high-precision plate-based image cytometric cell counting method for Nexcelom

INTERVIEWS & PODCASTS

Interviews are a great way to raise awareness within the vaccine community, with minimal resource requirements from your team.

We can interview up to three of your scientists, executives, partners or clients, with the resulting video, podcast and/or written version included in an issue of the online journal.

Examples of previous interviews for our clients:


Video and written

Stepping foot into a successful partnership to support your viral vector therapy through commercialization for Merck



Podcast and written

Precisely for CGT: automating aseptic filling for lowest volumes for Single Use Support



Podcasts
in a variety
of formats and
lengths can also be
produced, either in
series or as
one-offs



Key factors to consider for successful cell therapy manufacturing: a case study

Cell & Gene Therapy Insights 2022; 8(2): 241-249
10.18609/cgti.2022.039
PUBLISHED: 2 MARCH 2022

Valentina Becherucci, Øystein Amellem, Xavier de Mollerat du Jeu

You can listen to the [podcast at the bottom of this page](#) or read the interview below

[View pdf](#)

PODCAST INTERVIEW

QA: That makes sense. When you have a four-week manufacturing time, that means that the cells are undergoing several passages. Do you have criteria for how many passages you run in your manufacturing process, in order to not lose the cell's characteristics? Do you count the number of passages or the way you get to the desired end point of your drug?

VB: The data of all culture comes not after process validation. The goal is to reach the therapeutic design. The culture can be shorter - you can stop it at three weeks and not four weeks. It cannot be more than four weeks because, according to the literature, if you culture for more than that or five weeks, you can get some unwanted effects on cells. For example, you can get genetic variation that is not good for the patient. The four weeks come from our process validation, where we produced the batch of MSCs, and in four batches we saw that the variability was low in terms of the number of cells after four weeks of culture. We also checked other parameters of MSCs, for example the antigen expression of specific markers that must be positive or negative according to International Society of Cell Therapy.

XMJ: Valentina, in this four-week process, how do you ensure you maintain sterility? Do you do weekly QC monitoring on your process?

VB: In our process, we perform initial sterility before starting the culture directly on the bioreactor. Then, we perform an in-process control of sterility after two weeks of culture, and at the end of the culture, before freezing. In our process, cells will be frozen after four weeks of culture and then stored in liquid nitrogen until you get the patient. In this case, the sterility is performed both on cells and on the cell culture media, on the supernatant.

Q DH: What are the QC or analytical tests you implement in your process to ensure the safety and quality of the product?

VB: According to the regulatory specification, the testing methods must be validated, and mandatory regular testing includes testing of the sterility, endotoxin, mycoplasma, and hermes, and in our case, we also perform cell identification with flow cytometry. All these tests are performed as in-process control at different steps of the process, and also for the final release at the end of the process.

QA: Valentina - as you are using flasks, you operate in Class A and culture conditions. Have you tested bags, or a more closed system that you could operate in a hood?

VB: We have tested different kinds of flasks with more surface for culture. However, we do not use bags. Bags are only used in the final step for freezing and storage in liquid nitrogen. We only use open systems and flasks.

XMJ: You mentioned it is a Phase 2 process. As you move to Phase 3 and commercial, you will need to scale this process. How are you thinking about doing that?

Cell & Gene Therapy Insights | ISSN 2020-7900 | 243

For example:

Key factors to consider for successful cell therapy manufacturing: a case study for Thermo Fisher Scientific

VIDEO PRESENTATIONS

Our FastFacts videos are 10–15 minute edited presentations, accompanied by a poster summarising the key learning points. They are designed for the presentation of app notes, validation data, case studies, scientific posters or product demonstrations, and work well both for educational purposes and for lead generation.



Here are some examples:

FASTFACTS

A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing


Cell & Gene Therapy Insights 2021; 7(10), 389
10.18699/cgti.2021.064
PUBLISHED: 21 APRIL 2021

FASTFACTS

Joseph O'Connor

Watch the demonstration video or read the poster therapy manufacturing by minimizing manual touch

- ▶ Sample loading
- ▶ Activation
- ▶ Transduction or transfection
- ▶ Expansion
- ▶ Harvest

The poster for the Cocoon platform shows a workflow from sample loading to harvest. It features a large image of a multi-well plate and a small video player. The text describes the platform as a bespoke solution to minimize manual touchpoints in cell therapy manufacturing.

A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing for Lonza

FASTFACTS

Accelerating downstream analytical testing for gene therapy

Cell & Gene Therapy Insights 2022; 8(1), 23
10.18699/cgti.2022.025
PUBLISHED: 8 FEBRUARY 2022

Harald Ehlen

Watch the video or read the poster to learn:

- ▶ The benefits of rapid, reliable in-process testing
- ▶ How utilizing Slope Spectrometry can remove or reduce manual touchpoints
- ▶ Gene therapy case studies demonstrating use of the platform

The poster for accelerating downstream analytical testing for gene therapy features a flowchart of the testing process. It includes a small photo of Harald Ehlen and a bioRxiv preprint link. The text highlights the benefits of Slope Spectrometry in reducing manual touchpoints.

Accelerating downstream analytical testing for gene therapy for Repligen

FASTFACTS

Rapid Quantitation of Viral Vectors with Simple Plex Microfluidic Immunoassays


Cell & Gene Therapy Insights 2021; 7(12), 1725
10.18699/cgti.2021.067
PUBLISHED: 20 DECEMBER 2021

FASTFACTS

Nathan Steere

Watch the video or read the poster to learn:

- ▶ Traditional immunoassays offer excellent specificity for per and can be a significant source of variability
- ▶ Simple Plex viral titration assays, run on the Ella platform, to microfluidic circuits perform all reagent additions and wash
- ▶ Simple Plex assays utilize antibody reagents from industry

The poster for rapid quantitation of viral vectors with Simple Plex microfluidic immunoassays shows a comparison between traditional immunoassays and Simple Plex assays. It includes a small photo of Nathan Steere and a bioRxiv preprint link. The text describes the benefits of Simple Plex assays in reducing variability.

Rapid quantitation of viral vectors with Simple Plex microfluidic immunoassays for Bio-Techne

FASTFACTS

Cell and gene manufacturing: a case study approach to overcoming challenges

Cell & Gene Therapy Insights 2021; 7(2), 393
10.18699/cgti.2021.065
PUBLISHED: 29 APRIL 2021

FASTFACTS

Sean Werner

As cell therapy manufacturing moves from translational customers, and collaborators to better understand the

Watch the video or read the poster to learn:

- ▶ What are the biggest hurdles for cell and gene therapy
- ▶ What are the challenges with current technologies
- ▶ What are the biggest payoffs of solving these problems


The poster for cell and gene manufacturing challenges features a flowchart of the manufacturing process. It includes a small photo of Sean Werner and a bioRxiv preprint link. The text describes the challenges and payoffs of solving these problems.

Cell and gene manufacturing: a case study approach to overcoming challenges for Sexton Biotechnologies

Our FastFacts work well for educational and lead-generation purposes

INFOGRAPHICS

Our team are experts in communicating complex scientific information via visual formats, including infographics (static, voiced and animated), PPT presentations and illustrations. They work closely with your team to define contents and style, and the resulting content can be published in *Vaccine Insights* or simply provided to you for your own use.



Examples include:

Voiced infographic

Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide for Thermo Fisher Scientific







Animated infographic

Regulatory FAQs & common concerns for cell & gene therapy raw and starting materials for Thermo Fisher Scientific



SCIENTIFIC ILLUSTRATIONS



We work from your sketch or concept to create schematics or illustrations of your products or services

eBLASTS

We offer a strictly limited number of third-party eblasts to our registered users.



Our 2024 schedule is open for bookings. Please contact **Nicola McCall** at n.mccall@insights.bio.



PREMIUM SERVICES

We offer a number of premium options, both for content creation and for market research. These include:

- ▶ Bringing together KOL panels to discuss the topics of your choice, publishing the output as an ebook, video, and written roundtable, or other suitable content format
- ▶ Designing infographics, which can be animated and/or voiced, ideal for communicating complex technical or scientific information in an easily digestible format
- ▶ Inviting industry or academic Subject Matter Experts to join your live webinars to add their opinions to the discussion
- ▶ Building and deploying surveys amongst our users, providing detailed reports on the responses
- ▶ Bringing together focus groups to discuss your products/services, or topics of interest to you.



OUR OTHER PUBLICATIONS

In addition to *Vaccine Insights*, BioInsights also publishes:



Cell & Gene Therapy Insights

Launched in 2014, *Cell & Gene Therapy Insights* is our inaugural online, open access, peer-reviewed journal with a translational focus.


Cell & Gene Therapy Insights addresses the important challenges and advances in the field of cell and gene therapy, publishing original research, reviews, commentary articles, clinical trial reports and much more.



Immuno-Oncology Insights

Immuno-Oncology Insights is an open access, independently peer reviewed publication specifically designed to fill a number of clear and important gaps in the current slate of journals for the industrial and academic immuno-oncology communities.

Guided by an editorial board lead by Jon Wigginton and Renier J. Brentjens, *Immuno-Oncology Insights* places R&D challenges and progress across a wide variety of technology fields in context.



Nucleic Acid Insights

The latest addition to our publication portfolio, *Nucleic Acid Insights* provides online, peer-reviewed, open access content with a translational focus.

Nucleic Acid Insights is specifically designed to provide the need-to-know information required to successfully navigate this rapidly evolving space, covering all the major RNA and DNA technologies and modalities, including but not limited to: messenger RNA (mRNA); plasmid DNA; antisense oligonucleotides (ASO); phosphorodiamidate morpholino oligonucleotides (PMO); RNA interference (RNAi); small interfering RNA (siRNA); aptamers; micro RNA (miRNA); and guide RNA (gRNA).